ALMS Alumis Inc.
Alumis Inc. (ALMS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $507.0K.
Where they traded
Last open-market purchase: September 8, 2026 , by AKKARAJU SRINIVAS .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS 2 fills | Director | Buy | 546,581 | $10.63 | $5.8M | 4,937,026 | |
| AKKARAJU SRINIVAS 2 fills | Director | Sell | 96,131 | $10.55 | $1.0M | 4,663,735 −2% of holding | |
| AKKARAJU SRINIVAS 2 fills | Director | Buy | 440,140 | $11.17 | $4.9M | 4,711,801 | |
| Schroer John R. | Chief Financial Officer | Sell | 3,282 | $26.37 | $86.5K | 24,718 −11.7% of holding | |
| Hardiman Roy C. | Chief Business & Strategy Ofcr | Sell | 2,692 | $26.37 | $71.0K | 207,746 −1.3% of holding | |
| Goldstein David M | Chief Scientific Officer | Sell | 2,596 | $26.37 | $68.5K | 30,970 −7.7% of holding | |
| Bradley Mark Christopher | Chief Development Officer | Sell | 2,572 | $26.37 | $67.8K | 48,533 −5% of holding | |
| Drappa Jorn | Chief Medical Officer | Sell | 2,447 | $26.37 | $64.5K | 56,892 −4.1% of holding | |
| Pangali Sanam | Chief Legal Officer | Sell | 1,364 | $26.37 | $36.0K | 9,747 −12.3% of holding | |
| Pangali Sanam | Chief Legal Officer | Sell | 5,000 | $28.00 | $140.0K | 11,111 −31% of holding | |
| AKKARAJU SRINIVAS | Director | Buy | 588,235 | $17.00 | $10.0M | 1,853,488 | |
| 4 fills | Buy | 823,528 | $17.00 | $14.0M | 5,702,536 | ||
| Tananbaum James B. 2 fills | Director | Buy | 411,764 | $17.00 | $7.0M | 5,702,536 | |
| AKKARAJU SRINIVAS 3 fills | Director | Buy | 186,377 | $9.84 | $1.8M | 1,265,253 | |
| AKKARAJU SRINIVAS | Director | Buy | 66,027 | $8.18 | $540.1K | 1,078,876 | |
| AKKARAJU SRINIVAS | Director | Buy | 100,000 | $7.75 | $775.0K | 1,012,849 | |
| AKKARAJU SRINIVAS | Director | Buy | 96,000 | $7.55 | $724.8K | 912,849 | |
| AKKARAJU SRINIVAS | Director | Buy | 86,350 | $7.46 | $644.2K | 816,849 | |
| AKKARAJU SRINIVAS | Director | Buy | 38,702 | $7.64 | $295.7K | 730,499 | |
| AKKARAJU SRINIVAS | Director | Buy | 48,537 | $7.64 | $370.8K | 691,797 | |
| 2 fills | Buy | 144,424 | $7.38 | $1.1M | 2,614,215 | ||
| Tananbaum James B. | Director | Buy | 72,212 | $7.38 | $532.9K | 2,614,215 | |
| AKKARAJU SRINIVAS | Director | Buy | 125,743 | $7.20 | $905.3K | 643,260 | |
| 2 fills | Buy | 381,000 | $6.56 | $2.5M | 2,542,003 | ||
| Tananbaum James B. | Director | Buy | 190,500 | $6.56 | $1.2M | 2,542,003 | |
| AKKARAJU SRINIVAS | Director | Buy | 137,772 | $6.56 | $903.8K | 517,517 | |
| 2 fills | Buy | 234,748 | $6.19 | $1.5M | 2,351,503 | ||
| Tananbaum James B. | Director | Buy | 117,374 | $6.19 | $726.5K | 2,351,503 | |
| AKKARAJU SRINIVAS | Director | Buy | 102,652 | $6.05 | $621.0K | 379,745 | |
| 4 fills | Buy | 400,000 | $5.59 | $2.2M | 2,234,129 | ||
| Tananbaum James B. 2 fills | Director | Buy | 200,000 | $5.59 | $1.1M | 2,234,129 | |
| AKKARAJU SRINIVAS | Director | Buy | 914 | $5.51 | $5.0K | 277,093 | |
| AKKARAJU SRINIVAS | Director | Buy | 276,179 | $5.25 | $1.4M | 276,179 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.